Birmingham-based blood cancer charity Cure Leukaemia has announced a record-breaking 42% increase in their annual fundraising for the year ended October 31st 2013. The charity raised £863,474 last year, a figure that is worth over £8 million in potentially life saving drugs.
Pharmaceutical companies are creating potentially life-saving drugs at a faster rate than they can be tested and unless more specialist nurses are funded leukaemia patients will die without accessing these new treatments.
Funds raised by Cure Leukaemia enable Professor Charlie Craddock, at the Centre for Clinical Haematology in the Queen Elizabeth Hospital, to recruit additional specialist nurses. This extends the impact by getting patients across the region access to these pioneering drugs, helping save lives.
Three men who played a significant role in helping Cure Leukaemia achieve last year’s fundraising figure were Michelin starred chef Glynn Purnell, Partner and Head of the Birmingham Office of Legal firm Pinsent Masons Greg Lowson and Partner at the Birmingham office of Deloitte Richard Turnbull. They have all been appointed as Trustees of Cure Leukaemia, further evidence of the charity’s growing reputation in the Second City.
Glynn Purnell said, “Over the past two years I have worked closely with Cure Leukaemia as a Patron. I'm honoured to have been invited to further support the charity by becoming a Trustee.
“Professor Charlie Craddock and his team at the Centre for Clinical Haematology, right here in Birmingham provide ground-breaking research and treatment that is made possible through Cure Leukaemia. I’m a very proud Brummie and we, as a city, should be equally proud that Birmingham has a genuine opportunity to find a cure for this terrible disease.”
The Vice-President of the Birmingham Chamber of Commerce Greg Lowson said,
“Pinsent Masons have supported Cure Leukaemia for a number of years, which included me running my first and last half marathon!
I was delighted to accept their invitation to become a Trustee and I look forward to working with the Cure Leukaemia team to help the charity realise its ambitions.”
Richard Turnbull continued,
“My wife was treated for Hodgkins Lymphoma at the Centre for Clinical Haematology, so this is a cause close to my heart and I was delighted when Deloitte’s Birmingham office chose Cure Leukaemia as our local charity partner.
This world class charity based in Birmingham is something we can all be very proud of, and I’m looking forward to helping them achieve their goals as a Trustee.”
Cure Leukaemia Chief Executive James McLaughlin said,
“With another strong year of growth in fundraising it is imperative that we continue such growth to raise funds for more specialist nurses across the region.
I am thrilled to welcome Glynn, Greg and Richard as Trustees and I am sure their combined wealth of experience will prove to be a major asset to Cure Leukaemia for years to come.”